Cancer clinical trials in the region Provence-Alpes-Côte d'Azur

439 currently recruiting clinical trials
Region Provence-Alpes-Côte d'Azur
Phase 1 / Phase 2 Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN) #NCT05181735 #2021-000596-37
Required histologic types
Myelodysplastic syndromes (MDS)
Required histologic sub types
MDS de novo Secondary MDS
Required renal function statuses
> 60 ml/min 50-60 ml/min 30-50 ml/min
Required number of previous lines of therapy
1 2 3 or more
Required previous treatments
EPO / Growth factors
Required IPSS-R prognostic scores
Low Intermediate
Required IPSS-M prognostic scores
Low Moderately low
Excluded genetic anomalies
del(5q)
Excluded previous treatments
Systemic Treatment-Naive
27 recruiting sites
Groupe Francophone des Myélodysplasies
Phase 1 / Phase 2 Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN) #NCT05280509
Phase 2 Cohorte 2 (réponse sous-optimale au ruxolitinib)
Required histologic types
Myeloproliferative neoplasms (MPN)
Required histologic sub types
Primary myelofibrosis Secondary myelofibrosis
Required number of previous lines of therapy
1
Required previous treatments
Targeted therapy
Required DIPSS scores
Intermediate-1 Intermediate-2 High
Excluded previous treatments
Systemic Treatment-Naive
5 recruiting sites
Telios Pharma, Inc.
Phase 1 / Phase 2 Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN) #NCT05280509
Phase 2 Cohorte 1 Myélofibrose naïve au traitement par JAKi
Required histologic types
Myeloproliferative neoplasms (MPN)
Required histologic sub types
Primary myelofibrosis Secondary myelofibrosis
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Required DIPSS scores
Intermediate-1 Intermediate-2 High
Excluded previous treatments
Targeted therapy
5 recruiting sites
Telios Pharma, Inc.
Phase 1 / Phase 2 Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN) #NCT05601726
Syndromes myélodysplasiques
Required histologic types
Myelodysplastic syndromes (MDS)
Required histologic sub types
MDS de novo Secondary MDS
Required number of previous lines of therapy
1 2 3 or more
Required IPSS-R prognostic scores
High Very high
Excluded previous treatments
Systemic Treatment-Naive
3 recruiting sites
Advanced BioDesign
Phase 1 / Phase 2 Acute leukemia #NCT05601726
LAM
Required histologic types
Acute myeloid leukemia (AML)
Required number of previous lines of therapy
2 3 or more
Excluded previous treatments
Systemic Treatment-Naive
3 recruiting sites
Advanced BioDesign
Phase 1 / Phase 2 Acute leukemia #NCT04771130 #2021-003285-12
Parties 1, 2 et 3 cohortes LAM
Required histologic types
Acute myeloid leukemia (AML)
Required central nervous system lesions
None
Required renal function statuses
> 60 ml/min 50-60 ml/min
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Excluded genetic anomalies
BCR-ABL
Excluded previous treatments
Targeted therapy
3 recruiting sites
BeOne Medecines
Phase 1 / Phase 2 Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN) #NCT04176198 #2022-502597-16-00
Bras Nuvisertib (TP-3654) + Ruxolitinib
Required histologic types
Myeloproliferative neoplasms (MPN)
Required histologic sub types
Primary myelofibrosis Secondary myelofibrosis
Required number of previous lines of therapy
None
Required previous treatments
Targeted therapy
Required DIPSS scores
Intermediate-1 Intermediate-2 High
Required M-IPSS70+ v2.0 scores
Intermediate High
Required MYSEC-PM scores
Intermediate-1 Intermediate-2 High
8 recruiting sites
Sumitomo Pharma America, Inc.
Phase 1 / Phase 2 Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN) #NCT04176198 #2022-502597-16-00
Bras Nuvisertib (TP-3654) + Momelotinib
Required histologic types
Myeloproliferative neoplasms (MPN)
Required histologic sub types
Primary myelofibrosis Secondary myelofibrosis
Required number of previous lines of therapy
1 2 3 or more
Required previous treatments
Targeted therapy
Required DIPSS scores
Intermediate-1 Intermediate-2 High
Required M-IPSS70+ v2.0 scores
Intermediate High
Required MYSEC-PM scores
Intermediate-1 Intermediate-2 High
Excluded previous treatments
Systemic Treatment-Naive
8 recruiting sites
Sumitomo Pharma America, Inc.
Phase 1 / Phase 2 Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN) #NCT04176198 #2022-502597-16-00
Bras de monothérapie par nuvisertib
Required histologic types
Myeloproliferative neoplasms (MPN)
Required histologic sub types
Primary myelofibrosis Secondary myelofibrosis
Required number of previous lines of therapy
1 2 3 or more
Required previous treatments
Targeted therapy
Required DIPSS scores
Intermediate-1 Intermediate-2 High
Required M-IPSS70+ v2.0 scores
Intermediate High
Required MYSEC-PM scores
Intermediate-1 Intermediate-2 High
Excluded previous treatments
Systemic Treatment-Naive
8 recruiting sites
Sumitomo Pharma America, Inc.
Phase 1 / Phase 2 Breast cancer Stomach and esophageal cancer Sarcoma and GIST Cervical / Vulvar / Vaginal cancer #NCT06795412 #2025-521828-30-00
Partie 1 Autres tumeurs solides
Required histologic types
Stomach Oesogastric junction Bone sarcoma Soft tissue sarcoma Cervical cancer
Required histologic sub types
Adenocarcinoma Osteosarcoma Chordoma Squamous cell carcinoma Adenosquamous carcinoma
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Negative HR Positive
Required disease stage
Locally Advanced Metastatic
4 recruiting sites
Pyxis Oncology, Inc